Document Classification

Section Type: RESULTS

Text: Residual (123) I-mIBG positive metastatic disease after four (3-y-EFS 25. 7 + / -5. 3 % versus 55. 9 + / -7. 6 %, p = 0. 009 ; 3-y-OS 49. 8 + / -6. 1 % versus 65. 0 + / -7. 3 % ; p = 0. 021) and after six chemotherapy cycles (3-y-EFS 27. 5 + / -6. 2 % versus 47. 4 + / -6. 4 %, p = 0. 011 ; 3-y-OS 50. 5 + / -7. 1 % vs 60. 0 + / -6. 4 %, p = 0. 031) was associated with poor outcome.